Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $5,950,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at $79,321,592. This trade represents a 6.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, July 1st, Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00.
• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $81.18, for a total transaction of $2,435,400.00.

Kymera Therapeutics Price Performance

KYMR traded up $4.48 on Tuesday, hitting $119.24. The company had a trading volume of 827,668 shares, compared to its average volume of 1,247,150. The stock has a fifty day simple moving average of $87.91 and a 200-day simple moving average of $83.32. The firm has a market capitalization of $9.81 billion, a P/E ratio of -33.40 and a beta of 1.95. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.82) EPS. Equities research analysts expect that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on KYMR. B. Riley Financial increased their price target on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 8th. Morgan Stanley reaffirmed an “overweight” rating and set a $119.00 target price on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They set a “buy” rating and a $110.00 target price for the company. Finally, Canaccord Genuity Group upped their price target on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $121.41.

Institutional Trading of Kymera Therapeutics

Several institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP raised its holdings in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after acquiring an additional 1,061,957 shares during the last quarter. Finally, State Street Corp raised its holdings in Kymera Therapeutics by 9.4% in the 4th quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after acquiring an additional 190,383 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.